Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122697992 | 12269799 | 2 | F | 20160202 | 20160829 | 20160415 | 20160908 | EXP | GB-MHRA-EYC 00137739 | GB-MACLEODS PHARMACEUTICALS US LTD-MAC2016002631 | MACLEODS | 0.00 | Y | 0.00000 | 20160908 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122697992 | 12269799 | 1 | PS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | 0 | 75 | MG | ||||||||
| 122697992 | 12269799 | 2 | I | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
| 122697992 | 12269799 | 3 | I | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 40 MG, QD | 13520 | MG | Y | U | 0 | 40 | MG | ||||
| 122697992 | 12269799 | 4 | C | ASPIRIN. | ASPIRIN | 1 | 300 MG, UNK | Y | 0 | 300 | MG | ||||||||
| 122697992 | 12269799 | 5 | C | L-thyroxine Sodium | LEVOTHYROXINE SODIUM | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 6 | C | Alendronic acid | ALENDRONIC ACID | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 7 | C | REFRESH CELLUVISC | CARBOXYMETHYLCELLULOSE SODIUM | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 8 | C | EZETIMIBE. | EZETIMIBE | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 9 | C | LATANOPROST. | LATANOPROST | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 10 | C | RAMIPRIL. | RAMIPRIL | 1 | Unknown | 10 MG, QD | U | 0 | 10 | MG | |||||||
| 122697992 | 12269799 | 11 | C | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 122697992 | 12269799 | 12 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122697992 | 12269799 | 1 | Thrombosis prophylaxis |
| 122697992 | 12269799 | 2 | Transient ischaemic attack |
| 122697992 | 12269799 | 3 | Product used for unknown indication |
| 122697992 | 12269799 | 4 | Product used for unknown indication |
| 122697992 | 12269799 | 5 | Product used for unknown indication |
| 122697992 | 12269799 | 6 | Product used for unknown indication |
| 122697992 | 12269799 | 7 | Product used for unknown indication |
| 122697992 | 12269799 | 8 | Product used for unknown indication |
| 122697992 | 12269799 | 9 | Product used for unknown indication |
| 122697992 | 12269799 | 10 | Product used for unknown indication |
| 122697992 | 12269799 | 11 | Product used for unknown indication |
| 122697992 | 12269799 | 12 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122697992 | 12269799 | HO |
| 122697992 | 12269799 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122697992 | 12269799 | Drug interaction | |
| 122697992 | 12269799 | Facial paralysis | |
| 122697992 | 12269799 | Labelled drug-drug interaction medication error | |
| 122697992 | 12269799 | Transient ischaemic attack | |
| 122697992 | 12269799 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122697992 | 12269799 | 1 | 201412 | 0 | ||
| 122697992 | 12269799 | 3 | 20150301 | 20160202 | 0 |